Mast Cell Activation Syndrome (MCAS)
What it is, how it connects to Breast Implant Illness, and what you can do about it.
Written by Dr. Robert Whitfield, MD — Board-Certified Plastic Surgeon & Explant Specialist · Austin, Texas
Why I'm Talking About This
Over more than twenty years of performing explant surgery, I've noticed a pattern that the mainstream medical community is only beginning to acknowledge: a significant number of women who come to me with Breast Implant Illness don't just have BII. They have BII sitting on top of an already dysregulated immune system — and a major driver of that dysregulation is Mast Cell Activation Syndrome.
These are women who have been to ten doctors. They have a stack of normal labs. They've been told it's anxiety, stress, or that it's all in their head. It is not all in their head.
This page exists because you deserve a clear, honest explanation of what MCAS is, how it connects to your implants, and what an evidence-based workup and recovery plan actually looks like.
“An immune response to just about anything the body — or the mast cell — reads as foreign is going to set off an inflammatory reaction. Breast implants sitting in connective tissue create exactly that environment.”
— Dr. Tanya Dempsey, MD, MCAS Specialist
What Is Mast Cell Activation Syndrome?
Mast cells are white blood cells that live at every interface between your body and the outside world — your skin, gut lining, airways, bladder, connective tissue, and even the tissue surrounding your brain. They are your immune system's first responders. When they detect a threat — an allergen, an infection, a foreign body, or significant stress — they release a powerful chemical payload: histamine, tryptase, prostaglandins, cytokines, and other inflammatory mediators.
In a healthy system, that response is appropriate, targeted, and self-limiting. In MCAS, the trigger is hair-trigger sensitive. The mast cells fire when they shouldn't. They fire too hard. And they can't stop firing.
The result is a body locked in chronic low-grade systemic inflammation — affecting every organ system where mast cells live, which is essentially everywhere.
1 in 6
Current research estimates MCAS affects up to 17% of the general population. Most have no idea they have it.
A Brief History
MCAS as a recognized syndrome was first formally reported in 2007. The first international consensus diagnostic criteria weren't published until 2011–2012. Serious recognition in the broader medical community has only grown significantly over the last decade — and the COVID-19 pandemic dramatically accelerated awareness, because Long COVID symptoms and MCAS symptoms are nearly indistinguishable. SARS-CoV-2 directly activates mast cells. The pandemic didn't create MCAS — it forced medicine to finally pay attention to it.
Recognizing the Symptoms
MCAS is often missed because its symptoms span multiple organ systems and mimic dozens of other conditions. The hallmark is multi-system involvement — symptoms that don't fit neatly into one diagnosis, that come and go episodically, and that worsen with identifiable triggers like stress, certain foods, heat, hormonal shifts, or environmental exposures.
Skin & Immune
- •Flushing and redness
- •Hives (urticaria)
- •Itching (pruritus)
- •Angioedema (swelling)
- •New environmental sensitivities
- •Easy bruising
Gastrointestinal
- •Bloating and abdominal cramping
- •Nausea and vomiting
- •Chronic diarrhea or constipation
- •Food intolerances (often new)
- •Reflux
- •Unexplained weight loss
Neurological
- •Brain fog
- •Headaches and migraines
- •Anxiety (often sudden onset)
- •Cognitive impairment
- •Insomnia
- •Peripheral neuropathy
Cardiovascular
- •Heart palpitations
- •Low blood pressure
- •Fainting or near-syncope
- •POTS / orthostatic intolerance
- •Chest tightness
Respiratory
- •Wheezing
- •Chronic cough
- •Nasal congestion / stuffiness
- •Shortness of breath
- •Throat tightness
Musculoskeletal & Other
- •Joint pain and hypermobility
- •Muscle aches
- •Profound fatigue
- •Interstitial cystitis / bladder pain
- •Bone pain
- •Anaphylaxis or near-anaphylaxis
“If you've been to multiple doctors, have a stack of normal labs, and feel like something systemic is wrong that nobody can explain — MCAS belongs on your radar.”
— Dr. Robert Whitfield, MD
The MCAS & Breast Implant Illness Connection
Here is the clinical reality I see in my practice every week:
A breast implant is a foreign body. It sits in connective tissue — the exact tissue type where mast cells concentrate. Silicone particles can migrate from the implant shell into surrounding tissue, activating the immune system and triggering mast cell degranulation. The result is a chronic, low-grade inflammatory signal that never fully resolves — day after day, month after month, year after year.
For a woman whose mast cell system is already sensitized or dysregulated — whether from genetic predisposition, a prior infection, tick-borne illness, trauma, or an underlying connective tissue disorder — that implant acts like gasoline on a fire that was already burning.
| Symptom | Seen in BII | Seen in MCAS | Overlap |
|---|---|---|---|
| Profound fatigue | ✓ | ✓ | High |
| Brain fog / cognitive impairment | ✓ | ✓ | High |
| Joint pain | ✓ | ✓ | High |
| GI symptoms / food intolerances | ✓ | ✓ | High |
| Skin rashes / flushing | ✓ | ✓ | High |
| Anxiety / mood changes | ✓ | ✓ | High |
| Histamine / allergic reactions | ✓ | ✓ | High |
| POTS / dysautonomia | ✓ | ✓ | High |
| Autoimmune markers | ✓ | ✓ | Moderate |
| Capsular contracture | ✓ | — | BII-specific |
| Anaphylactic episodes | — | ✓ | MCAS-specific |
An important clinical point: removing the implant eliminates the ongoing foreign body trigger. But if the mast cell system was already dysregulated before the implant — or has become chronically sensitized — explant alone may not fully resolve symptoms. Identifying and treating underlying MCAS is often the missing piece in patients who don't feel completely better after explant surgery.
How MCAS Is Diagnosed
Diagnosis requires meeting three consensus criteria established by international expert panels, including the European Competence Network on Mastocytosis and the American Academy of Allergy, Asthma & Immunology (AAAAI).
Clinical Criterion
Recurrent, episodic symptoms involving two or more organ systems simultaneously. Symptoms must be consistent with mast cell mediator release and not explained by another condition.
Laboratory Criterion
Objective evidence of mast cell activation — ideally a rise in serum tryptase of at least 20% plus 2 ng/mL above the individual's personal baseline, drawn within 1–4 hours of a symptomatic episode. Alternatively, elevated urinary mast cell mediators (N-methylhistamine, prostaglandin D2 metabolites, leukotriene E4) can be used.
Response Criterion
Meaningful symptom improvement with medications that target mast cell mediators — H1 antihistamines, H2 antihistamines, leukotriene inhibitors, or mast cell stabilizers such as cromolyn sodium or omalizumab.
Testing Overview
| Test | What It Measures | Notes | Level |
|---|---|---|---|
| Serum Tryptase (acute + baseline) | Primary mast cell marker | Must be drawn within 1–4 hrs of episode; compare to personal baseline | Standard |
| 24-hr Urine N-Methylhistamine | Histamine metabolite | More reliable than serum histamine; collect during symptomatic period | Standard |
| Urine Prostaglandin D2 / 11β-PGF2α | Prostaglandin mediators | Elevated in many MCAS patients; useful when tryptase is normal | Standard |
| Urine Leukotriene E4 | Leukotriene mediators | Can rise post-activation; less specific but useful adjunct | Standard |
| Mayo Clinic Random Urine Panel (MCMRU) | Multiple mast cell mediators | New panel; no timed collection required; allows targeted treatment selection | Advanced |
| KIT D816V Mutation (peripheral blood) | Clonal mast cell disease | Rules in/out systemic mastocytosis; high-sensitivity assay preferred | Advanced |
| Hereditary Alpha-Tryptasemia (HαT) Testing | Genetic tryptase baseline elevation | Important if baseline tryptase is elevated without symptoms | Advanced |
| FISH Assay (Bartonella, Babesia) | Direct pathogen detection | Detects organisms directly without relying on antibody response; critical for patients with immune dysregulation who may not mount normal antibody titers | Molecular |
| PCR / ddPCR for tick-borne co-infections | Borrelia, Bartonella, Babesia, Ehrlichia | Standard antibody testing misses significant percentage; molecular testing essential in complex patients | Molecular |
| GI-MAP or equivalent PCR Stool Panel | Gut parasites and pathogens | Blastocystis, Giardia, Cryptosporidium, Dientamoeba frequently missed on standard O&P; gut infections are significant mast cell triggers | Molecular |
“Standard antibody testing fails a meaningful percentage of patients with chronic infections because immune dysregulation — which is intrinsic to MCAS — blunts the antibody response that these tests rely on. Molecular testing looks for the organism directly. That changes everything.”
— Dr. Tanya Dempsey, MD
How I Approach MCAS Patients Surgically
Patients with known or suspected MCAS represent some of the most sensitive surgical candidates I see. They require a fundamentally different preparation and recovery strategy — one built around minimizing immunological provocation at every stage of the perioperative journey.
My approach draws on two core frameworks: the SHARP Method for preoperative preparation and a rigorously structured Enhanced Recovery After Surgery (ERAS) protocol targeting nerve pain, nausea, and systemic inflammation — the three primary pathways through which surgery activates mast cells.
Sharp Method — Preoperative Preparation
Patients begin a structured preparation protocol before surgery designed to reduce baseline inflammatory load, optimize nutritional status, and stabilize the mast cell response prior to any operative intervention. This is not a standard pre-op checklist — it is a clinical strategy to lower the immunological bar before we begin.
ERAS Protocol — Targeting the Three Pathways
My ERAS protocol is specifically engineered to minimize the three surgical triggers most relevant to MCAS patients: nerve pain activation, nausea (a common mast cell mediator response), and systemic inflammation. Every drug selection, timing decision, and dosing strategy is made with these three pathways in mind.
Ultrasound-Guided Nerve Blocks
I perform all nerve blocks personally under ultrasound guidance using long-acting local anesthetics. For MCAS patients, this is not optional — it is essential. Providing superior regional anesthesia reduces total systemic opioid exposure, which is one of the most potent mast cell triggers in the surgical environment. Less opioid means less mast cell activation.
Avoidance of Long-Acting Narcotics
I deliberately avoid long-acting narcotics in all patients, with particular attention in MCAS patients. Opioids are well-documented mast cell degranulators. My goal is to provide such effective regional anesthesia and multimodal pain management that narcotics become unnecessary — not reduced, unnecessary.
Same-Day Outpatient Discharge
Our surgery center was specifically designed for same-day outpatient discharge. Getting MCAS patients home — in their own controlled environment, away from hospital-acquired exposures and sensory overload — is part of the recovery strategy, not a cost-cutting measure.
Next-Day Recovery Sequence
Beginning the morning after surgery, patients access our dedicated recovery sequence: the Human Generator, Flowpresso lymphatic massage with NanoVi therapy, hyperbaric oxygen therapy, and red light therapy. Each modality has mechanistic support for reducing post-surgical inflammation, supporting lymphatic clearance, and improving autonomic nervous system function — all critical for MCAS patients.
“For patients with mast cell activation syndrome, the goal of surgery is not just technical precision — it is providing the least possible immunological stimulus at every stage, from preoperative preparation through recovery. We build the entire perioperative environment around that principle.”
— Dr. Robert Whitfield, MD
MCAS Treatment Overview
MCAS treatment is highly individualized and typically involves a layered approach: reducing trigger load, stabilizing mast cell activity, and blocking the downstream effects of mediator release. Working with a physician who specializes in mast cell disorders is critical.
| Category | Examples | Target |
|---|---|---|
| H1 Antihistamines | Cetirizine, loratadine, fexofenadine, hydroxyzine | Block histamine at H1 receptors — skin, airway, neurological symptoms |
| H2 Antihistamines | Famotidine, ranitidine | Block histamine at H2 receptors — GI symptoms, acid production |
| Leukotriene Inhibitors | Montelukast (Singulair) | Block leukotriene C4/D4 — respiratory, inflammatory symptoms |
| Mast Cell Stabilizers | Cromolyn sodium (oral), ketotifen | Prevent mast cell degranulation before it occurs |
| Prostaglandin Inhibitors | Aspirin (low-dose, if tolerated), NSAIDs | Block prostaglandin D2 production — cardiovascular and flushing symptoms |
| Biologic / Immunomodulator | Omalizumab (Xolair) | IgE-blocking antibody — reduces mast cell activatability at the receptor level |
| Low-Histamine Diet | Elimination of aged cheeses, fermented foods, alcohol, processed meats | Reduce total histamine burden; allow identification of food triggers |
| Trigger Reduction | Stress management, sleep optimization, environmental controls | Lower the total mast cell activation load |
| Treat Upstream Drivers | Address tick-borne infections, gut parasites, gut dysbiosis, SIBO | Eliminate infectious mast cell triggers; most critical and most often overlooked |
Frequently Asked Questions
Can breast implants cause MCAS?+
I had my implants removed but still don't feel better. Could MCAS be why?+
How do I find a doctor who understands MCAS?+
Is MCAS genetic?+
Will I need medication forever?+
Can children have MCAS?+
Is there a cure for MCAS?+
Conditions That Overlap with MCAS in BII Patients
POTS & Dysautonomia
Autonomic nervous system dysfunction driven by immune activation and GPCR autoantibodies
Lyme Disease & BII
Borrelia infection drives mast cell activation and compounds BII immune burden
BII Symptoms
The full spectrum of breast implant illness symptom patterns
Lab Testing
Advanced testing protocols for BII and related conditions
Ready to Take the Next Step?
Whether you're preparing for explant surgery or navigating unexplained symptoms, Dr. Whitfield's team is here to help.
This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Mast Cell Activation Syndrome is a complex condition requiring individualized evaluation by a qualified physician. The information presented here is based on published research and clinical experience but should not replace professional medical consultation. If you believe you may have MCAS, please seek evaluation from a physician experienced in mast cell disorders.